Daily as of 3 Nov 16:00 ET
- Price
- between the two $29.20 vs 50 $30.50 / 200 $20.23
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 20 Nov 2024 · projected 27 bars out
AMLX | Amylyx PharmaceuticalsNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history
$29.20
+$1.16 (+4.14%)
Amylyx Pharmaceuticals (AMLX) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2023.
The 50 SMA sits above the 200 on the daily, with no cross projected inside the 30 bars Cruxta tracks. On both the weekly and the 4-hour, price sits above the 50 and the 200; on the daily it is between the two.
Timeframe summary
Weekly as of 30 Oct 16:00 ET
- Price
- above both $28.86 vs 50 $18.76 / 200 $14.02
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross week of 3 Aug 2026 · projected 27 bars out
4-hour as of 3 Nov 16:00 ET
- Price
- above both $29.20 vs 50 $27.95 / 200 $25.63
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 30 Jun 2026 · projected 29 bars out
Cross history
| Crossed | Direction | Timeframe | Projected | Cross test |
|---|---|---|---|---|
| week of 3 Aug 2026 | 🟨Golden moderate | weekly | 27 bars out | — |
| 30 Jun 2026 | 🟨Golden | 4-hour | 29 bars out | Not tested |
| 1 Jun 2026 | 💀Death | 4-hour | 26 bars out | 2 bar cross test |
| 30 Jan 2026 | 🟨Golden | 4-hour | 30 bars out | 2 bar cross test |
| 8 Jan 2026 | 💀Death | 4-hour | 24 bars out | 6 bar cross test |
About AMLX
ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$40.5M
4-hour coverageYes, since Oct 2025
History on recordSince 2023
SectorHealthcare
Cap bandmid